Literature DB >> 21971737

Cerebrospinal fluid stimulates leptomeningeal and meningioma cell proliferation and activation of STAT3.

Mahlon D Johnson1, Mary O'Connell, Michael Facik, Paul Maurer, Babak Jahromi, Webster Pilcher.   

Abstract

The role of cerebrospinal fluid (CSF) in the pathogenesis of meningiomas is unknown. Cell cultures from three human leptomeninges, five WHO grade I and seven grade II meningiomas were treated with remnant CSF from 22 patients with no central nervous system disease and normal cell indices. Cells were evaluated by CyQUANT for DNA synthesis/cell proliferation and by western blots for phosphorylation/activation of growth regulatory pathways activated in meningiomas including JAK1-STAT3, MEK1-p44/42MAPK, Akt-mTOR and Rb. Analysis of Caspase 3 activation and survivin was also performed. Finally, the effects of PDGF neutralizing antibody and cucurbitacin, a STAT3 inhibitor on CSF stimulation were tested. Compared to controls and the mitogen PDGF-BB, various CSF samples significantly stimulated DNA synthesis/cell proliferation in 20 and 22 week leptomeningeal cultures and all of the grade I and II meningioma cells tested. Collectively CSF samples, from multiple different patients, stimulated DNA synthesis in tests of 23 of 32 grade I and 18 of 28 grade II meningioma cells. CSF stimulated phosphorylation/activation of STAT3 and reduced p44/42 MAPK in the leptomeningeal, all three grade I and 1 of three grade II meningioma cells. CSF did not affect Caspase 3 activity or survivin levels. PDGF neutralizing antibody had no effect on CSF stimulation but cucurbitacin blocked PDGF and CSF stimulation. While there are limitations to the CSF available since they were not from "normal" volunteers, the studies suggest that, in some settings, CSF is potentially mitogenic to leptomeningeal and meningioma cells and may act, in part, via activation of STAT3.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21971737     DOI: 10.1007/s11060-011-0736-9

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  40 in total

1.  Discovery of a novel shp2 protein tyrosine phosphatase inhibitor.

Authors:  Liwei Chen; Shen-Shu Sung; M L Richard Yip; Harshani R Lawrence; Yuan Ren; Wayne C Guida; Said M Sebti; Nicholas J Lawrence; Jie Wu
Journal:  Mol Pharmacol       Date:  2006-05-22       Impact factor: 4.436

2.  Increased intrathecal TGF-beta1, but not IL-12, IFN-gamma and IL-10 levels in Alzheimer's disease patients.

Authors:  E Rota; G Bellone; P Rocca; B Bergamasco; G Emanuelli; P Ferrero
Journal:  Neurol Sci       Date:  2006-04       Impact factor: 3.307

Review 3.  Why the embryo still matters: CSF and the neuroepithelium as interdependent regulators of embryonic brain growth, morphogenesis and histiogenesis.

Authors:  Angel Gato; Mary E Desmond
Journal:  Dev Biol       Date:  2009-01-03       Impact factor: 3.582

4.  Transforming growth factor beta and monocyte chemotactic protein-1 are elevated in cerebrospinal fluid of immunocompromised patients with HIV-1 infection.

Authors:  M D Johnson; P Kim; W Tourtellotte; C F Federspiel
Journal:  J NeuroAIDS       Date:  2004

5.  Different activation of mitogen-activated protein kinase and Akt signaling is associated with aggressive phenotype of human meningiomas.

Authors:  Christian Mawrin; Tina Sasse; Elmar Kirches; Siegfried Kropf; Thomas Schneider; Christoph Grimm; Claudia Pambor; Christian K Vorwerk; Raimund Firsching; Uwe Lendeckel; Knut Dietzmann
Journal:  Clin Cancer Res       Date:  2005-06-01       Impact factor: 12.531

6.  Evidence for phosphatidylinositol 3-kinase-Akt-p7S6K pathway activation and transduction of mitogenic signals by platelet-derived growth factor in meningioma cells.

Authors:  Mahlon D Johnson; Evelyn Okedli; Ann Woodard; Steven A Toms; George S Allen
Journal:  J Neurosurg       Date:  2002-09       Impact factor: 5.115

7.  Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice.

Authors:  Michelle A Blaskovich; Jiazhi Sun; Alan Cantor; James Turkson; Richard Jove; Saïd M Sebti
Journal:  Cancer Res       Date:  2003-03-15       Impact factor: 12.701

8.  Accumulation of nerve growth factor in cerebrospinal fluid and biological activity following neurosurgery.

Authors:  M Sagoh; K Yoshida; H Wakamoto; H Kamiguchi; M Otani; R Shiobara; S Toya
Journal:  Neurol Med Chir (Tokyo)       Date:  1995-07       Impact factor: 1.742

9.  Secretion of interleukin-6 by human meningioma cells: possible autocrine inhibitory regulation of neoplastic cell growth.

Authors:  T Todo; E F Adams; B Rafferty; R Fahlbusch; T Dingermann; H Werner
Journal:  J Neurosurg       Date:  1994-09       Impact factor: 5.115

10.  Platelet-derived growth factor (PDGF) in neoplastic and non-neoplastic cystic lesions of the central nervous system and in the cerebrospinal fluid.

Authors:  M Nistér; P Enblad; G Bäckström; T Söderman; L Persson; C H Heldin; B Westermark
Journal:  Br J Cancer       Date:  1994-05       Impact factor: 7.640

View more
  4 in total

1.  APOBEC3B expression in human leptomeninges and meningiomas.

Authors:  Mahlon D Johnson; Jay E Reeder; Mary O'Connell
Journal:  Oncol Lett       Date:  2016-11-10       Impact factor: 2.967

2.  STAT3 activation and risk of recurrence in meningiomas.

Authors:  Mahlon Johnson; Mary O'Connell; Kevin Walter
Journal:  Oncol Lett       Date:  2017-02-14       Impact factor: 2.967

Review 3.  Genetic/molecular alterations of meningiomas and the signaling pathways targeted.

Authors:  Patrícia Domingues; María González-Tablas; Álvaro Otero; Daniel Pascual; Laura Ruiz; David Miranda; Pablo Sousa; Jesús María Gonçalves; María Celeste Lopes; Alberto Orfao; María Dolores Tabernero
Journal:  Oncotarget       Date:  2015-05-10

4.  Cucurbitacin I blocks cerebrospinal fluid and platelet derived growth factor-BB stimulation of leptomeningeal and meningioma DNA synthesis.

Authors:  Mahlon D Johnson; Mary J O'Connell; Kevin Walter
Journal:  BMC Complement Altern Med       Date:  2013-11-04       Impact factor: 3.659

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.